title: The separate impact of tight control schemes and disease activity on quality of life in patients with early rheumatoid arthritis: results from the CAMERA trials.
abstract: OBJECTIVE
  To examine in patients with early rheumatoid arthritis (RA) whether quality of life (QoL), independently of disease activity, is affected by tight control treatment strategy schemes.
  
  
  METHODS
  In the Computer Assisted Management in Early RA (CAMERA) trials, patients with early RA, disease duration <1 year, no prior use of DMARDs) had been randomised to a methotrexate (MTX)-based tight control strategy or usual care (CAMERA study) or to 10 mg/d prednisone or placebo both added from start to a MTX-based tight control strategy (CAMERA-II study). In either study, randomisation to the more intensive strategy resulted in lower disease activity. To assess QoL, the 'Influence of Rheumatic Diseases on General Health and Lifestyle' questionnaire (IRGL) was used. Baseline and 1- and/or 2-year measurements were analysed with regression analyses with the IRGL (sub)scales as outcome variables and treatment strategy and disease activity assessing 28 joints (DAS28) as independent variables, correcting for baseline values of each scale and possible confounders (gender, age, rheumatoid factor status).
  
  
  RESULTS
  There was no clear association between either of the treatment strategies and QoL, but a decrease in DAS28 was associated with improvement in the majority of QoL (sub)scales.
  
  
  CONCLUSIONS
  No independent effect of the specific tight control strategies schemes on QoL was found, while there was a clear disease activity related effect. Thus frequent outpatient visits or the inclusion of prednisone in a tight control strategy did not negatively influence QoL.
authors.affiliation: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands. mjurgens@umcutrecht.nl.
authors.forename: M S
authors.initials: MS
authors.lastname: Jurgens
authors.forename: P M J
authors.initials: PM
authors.lastname: Welsing
authors.forename: R
authors.initials: R
authors.lastname: Geenen
authors.forename: M F
authors.initials: MF
authors.lastname: Bakker
authors.forename: Y
authors.initials: Y
authors.lastname: Schenk
authors.forename: Y A
authors.initials: YA
authors.lastname: de Man
authors.forename: J W J
authors.initials: JW
authors.lastname: Bijlsma
authors.forename: F P J G
authors.initials: FP
authors.lastname: Lafeber
authors.forename: J W G
authors.initials: JW
authors.lastname: Jacobs
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000523:psychology*; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D010919:Placebos; D011241:Prednisone / Q000008:administration & dosage*; D011788:Quality of Life / Q000523:psychology*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D013813:Therapy, Computer-Assisted; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D005938:Glucocorticoids; D010919:Placebos; D011241:Prednisone; D008727:Methotrexate